Wednesday, 18 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:12 PM ET 8-K
Financial Results Alpha Teknova, Inc. TKNO

Alpha Teknova Financial Results

Alpha Teknova reported record third quarter 2026 revenue of $12.7 million, a 22% increase year-over-year, driven by strong demand in Clinical Solutions and Lab Essentials. Based on the performance, the company raised its full-year 2026 revenue guidance to a range of $46 million to $48 million.

Term
Q3 2026

“We posted record revenue for the second consecutive quarter. Growth was driven by increased sales of products to life science tools and diagnostics, and to biopharma customers. Notably, there was an increase in purchases of our custom products by small and mid-sized biotech customers and their associated contract manufacturers, which we believe is an early indication of biotech funding improvements over the past four quarters.”

Stephen Gunstream, President and Chief Executive Officer

“We delivered excellent financial results in the third quarter 2026 compared to 2025, highlighted by 22% revenue growth and a significant improvement in Adjusted EBITDA and Free Cash Outflow. We are therefore raising our 2026 revenue guidance to $46-48 million and maintaining our expectations for full-year Free Cash Outflow of less than $8 million.”

Matt Lowell, Chief Financial Officer
4:12 PM ET 8-K
Investor Presentation Southern Missouri Bancorp, Inc. SMBC

Southern Missouri Bancorp Investor Presentation

Southern Missouri Bancorp, Inc. filed an investor presentation to be used at the Hovde Group Financial Services Conference on November 5, 2026. The presentation provides an overview of the company's mission, values, and retail and business banking offerings for the first quarter of fiscal 2027.

4:12 PM ET 8-K
Financial Results Paycom Software, Inc. PAYC

Paycom Software Financial Results

Paycom Software reported third quarter 2026 total revenues of $543.8 million, a 10.2% increase year-over-year, driven by strong growth in recurring revenues. The company achieved GAAP net income of $133.2 million and raised its full-year 2026 revenue guidance to a range of $2.213 billion to $2.218 billion.

Term
Q3 2026

“Our strong third-quarter results reflect the tremendous ROI clients are realizing from the automated decisioning logic built into our platform. Our software and infrastructure allow us to develop, release, host, distribute, and service technology that delivers greater value to our clients and Paycom. This represents a powerful advantage across our large and expanding TAM. Thanks to our strong performance, we are once again raising our full-year outlook.”

Chad Richison, Paycom founder and CEO
4:12 PM ET 8-K
Financial Results Western Midstream Partners, LP WES

Western Midstream Partners Financial Results

Western Midstream Partners reported third-quarter 2026 results featuring record natural-gas throughput of 5.9 Bcf/d and a 12% year-over-year increase in Adjusted EBITDA to $708.3 million. The company reaffirmed its full-year 2026 Adjusted EBITDA guidance of $2.75 billion to $2.95 billion while noting that capital expenditures are expected to be slightly above the high end of the $850 million to $1.0 billion range due to accelerated producer activity.

Term
Q3 2026

“WES achieved record natural-gas throughput, partnership-wide and in the Delaware Basin, driven by increased throughput from our legacy assets and a full quarter of contribution from the Brazos Delaware acquisition that closed in June. The Brazos integration is progressing as expected, and we anticipate tying those assets into our West Texas Complex by mid-December, enabling us to reduce offloads and generate more value for WES unitholders.”

Oscar K. Brown, President and Chief Executive Officer
4:12 PM ET 8-K
Financial Results Quinstreet, Inc QNST

Quinstreet Financial Results

QuinStreet reported record fiscal first quarter 2027 results with revenue of $416.7 million, up 46% year-over-year, and net income of $17.0 million. The company raised its full-year fiscal 2027 outlook, citing continued strength in Auto Insurance carrier demand and momentum in its Home Services platform.

Term
Q1 2027

“The September quarter, our fiscal Q1 was another record quarter and a good start to our fiscal year 2027. We grew revenue 46% year-over-year, and we grew adjusted EBITDA 108% year-over-year.”

Doug Valenti, CEO of QuinStreet

“We are raising our outlook for full fiscal year 2027. We now expect full fiscal year 2027 revenue to be between $1.5 and $1.6 billion, and full fiscal year adjusted EBITDA to be between $155 and $165 million.”

Doug Valenti, CEO of QuinStreet
4:12 PM ET 8-K
Financial Results Adma Biologics, Inc. ADMA

Adma Biologics Financial Results

ADMA Biologics reported third quarter 2026 financial results, highlighted by a 5% year-over-year increase in total revenue to $141.1 million and a 37% increase in GAAP net income to $49.9 million. The growth was primarily driven by ASCENIV revenue, which rose 31% to $124.7 million due to expanding physician adoption and patient starts. The company reiterated its full-year 2026 revenue guidance of at least $530 million while increasing its adjusted earnings outlook.

Term
3 months ended September 30, 2026

“Our third quarter results demonstrate ADMA’s ability to translate accelerating ASCENIV demand into substantial earnings growth. ASCENIV revenue increased 31% year-over-year, driven by expanding physician adoption, new patient starts and growing end-user utilization.”

Adam Grossman, President and Chief Executive Officer

“Our expanding real-world health outcomes evidence strengthens ASCENIV’s clinical value proposition among medically complex primary immunodeficiency patients and supports growing commercial adoption. With our yield-enhanced manufacturing capabilities, robust cash generation and disciplined capital allocation, we believe ADMA is well positioned to deliver sustained, profitable growth and long-term stockholder value creation.”

Adam Grossman, President and Chief Executive Officer
4:12 PM ET 8-K
Financial Results Evolus, Inc. EOLS

Evolus Financial Results

Evolus reported Q3 2026 global net revenue of $78.0 million, a 13% increase year-over-year, driven by growth in its Jeuveau toxin and HA gel portfolio. The company achieved its fourth consecutive quarter of positive Adjusted EBITDA at $1.2 million and reaffirmed its full-year 2026 revenue guidance of $330 million to $337 million.

Term
Q3 2026

“Our third quarter results demonstrate the continued strength of our commercial execution and the progress we are making in building a diversified global performance beauty company. Jeuveau® remains a durable growth engine, and our hyaluronic acid (HA) gel portfolio is gaining meaningful share and becoming an increasingly important contributor to the business.”

David Moatazedi, President and Chief Executive Officer

“Along with our commercial progress, we are building a robust innovation pipeline that broadens our long-term opportunity. Our partnership with IBSA to develop and commercialize Profhilo® in the United States establishes the foundation for skin quality as a third category within our facial injectable platform.”

David Moatazedi, President and Chief Executive Officer
4:12 PM ET Form 4
Insider Selling Regeneron Pharmaceuticals, Inc. REGN

Regeneron Pharmaceuticals Insider George L. Sing Sells $20.4M of Stock

George L. Sing sold 21,129 shares of Regeneron Pharmaceuticals, Inc. at $960.57 to $970.18 a share (average $964.38) in 9 transactions, worth $20.4M in total on Nov 2, 2026. Shares held after the trade: 25,147 (-0.8%).

Value
$20.4M
Shares
21,129
Average price
$964.38
Holding change
-0.8%
Trade date
Nov 2, 2026
4:12 PM ET 10-Q
Financial Results Lesaka Technologies Inc LSAK

Lesaka Technologies Q1 2026 Results: Net Loss of $4.18M, Loss Narrows

Lesaka Technologies reported its Q1 2027 results, showing continued operations across its Merchant, Consumer, and Enterprise segments. The company maintains significant credit facilities with Nedbank and RMB to support its microlending and merchant finance operations, while managing a complex capital structure involving various restricted stock and employee option plans.

Key figure
Net loss $4.18M
4:11 PM ET 8-K
Investor Presentation Wesbanco Inc WSBC

Wesbanco Investor Presentation

WesBanco, Inc. filed its Q4 2026 investor presentation to be used at various conferences and events throughout the fourth quarter. The presentation highlights the company's $28.5 billion in assets, its organic loan growth strategy, and its focus on expanding into high-growth markets while maintaining a disciplined expense culture.

4:11 PM ET 8-K
Financial Results Acadia Healthcare Company, Inc. ACHC

Acadia Healthcare Company Financial Results

Acadia Healthcare reported Q3 2026 revenue of $895.3 million, a 5.1% increase year-over-year, driven by strong performance in acute inpatient psychiatric facilities. While net income slightly decreased to $34.5 million, the company raised its full-year 2026 financial guidance based on positive operational momentum and facility expansions.

Term
Q3 2026

“Acadia delivered strong results in the third quarter, and our positive momentum is driving our increased full-year guidance. We remain focused on our key priorities, including expanding access to quality patient care and consistent operational execution with financial discipline.”

Debbie Osteen, Chief Executive Officer of Acadia
4:11 PM ET 8-K
Financial Results Alto Ingredients, Inc. ALTO

Alto Ingredients Financial Results

Alto Ingredients reported Q3 2026 net income of $12.7 million on net sales of $257.9 million, driven by core operations and 45Z tax credit earnings. The company reduced its debt by $26.5 million year-to-date and expects to generate at least $20 million in net 45Z tax credits for the full year 2026.

Term
Q3 2026

“We delivered positive gross profit, income from operations, net income and adjusted EBITDA for the third quarter demonstrating the earnings power of our core operations with 45Z tax credit earnings adding to an already solid foundation.”

Bryon McGregor, President and Chief Executive Officer

“Through our efforts to lower our carbon scores at our Columbia facility and Pekin dry mill, we now expect to generate a minimum of $20 million, net of monetization costs, in 2026.”

Bryon McGregor, President and Chief Executive Officer
4:11 PM ET 8-K
Financial Results Matson, Inc. MATX

Matson Financial Results

Matson reported strong Q3 2026 results with net income of $209.4 million and revenue of $1.11 billion, driven by high demand and elevated freight rates in its China service. The company raised its full-year outlook, expecting Q4 2026 consolidated operating income to be approximately 50% higher than the prior year period.

Term
Q3 2026

“Matson had a stronger-than-expected third quarter. Our China service performed well, with its speed and reliability serving as important differentiators amid continued pressure on global shipping networks and congestion at key Asia ports.”

Matt Cox, Matson’s Chairman and Chief Executive Officer

“Looking ahead, we expect the strong demand and elevated freight rates we experienced in our China service in the third quarter to continue through year end and into early 2027.”

Matt Cox, Matson’s Chairman and Chief Executive Officer
4:11 PM ET 8-K
Financial Results OnKure Therapeutics, Inc. OKUR

OnKure Therapeutics Financial Results

OnKure Therapeutics reported third quarter 2026 financial results and provided updates on its PI3Kα pan-mutant-selective inhibitor pipeline. The company remains on track to submit IND applications for OKI-355 (vascular anomalies) and OKI-345 (breast cancer) in the first half of 2027, while also launching the PANORAMA disease registry.

“We continue to advance the development of next-generation PI3Kα pan-mutant-selective inhibitors through our pipeline, including OKI-355 in vascular anomalies and OKI-345 in breast cancer. Both of our lead programs remain on track for IND submissions in the first half of 2027.”

Nicholas Saccomano, Ph.D., President and Chief Executive Officer

“People living with vascular anomalies remain underserved, and we believe OnKure has an opportunity to help shape the future of treatment for this community. Mutations in the PIK3CA gene drive a range of vascular malformations, providing a compelling rationale for our development of OKI-355, which is designed to provide broad coverage across these mutations.”

Samuel Agresta, M.D., Chief Medical Officer
4:11 PM ET Form 4
Insider Buying Autonation, Inc. AN

Autonation CEO and Director Michael Mark Manley Buys $1.03M of Stock

Michael Mark Manley, CEO and Director, bought 5,600 shares of Autonation, Inc. at $183.84 to $184.65 a share (average $184.11) in 2 transactions, worth $1.03M in total on Nov 2, 2026. Shares held after the trade: 157,186 (+1.2%).

Value
$1.03M
Shares
5,600
Average price
$184.11
Role
CEO and Director
Holding change
+1.2%
Trade date
Nov 2, 2026
4:11 PM ET 10-Q
Financial Results Revolution Medicines, Inc. RVMD

Revolution Medicines Q3 2026 Results: Net Loss of $407M, Loss Widens

Revolution Medicines reported its first product revenue of $197.6 million for the quarter ended September 30, 2026, following the commercialization of RASONQUE® (daraxonrasib). The company significantly strengthened its balance sheet, ending the period with approximately $3.65 billion in cash and marketable securities, though it continues to operate with a substantial accumulated deficit of $4.37 billion.

Key figure
Net loss $407M
4:11 PM ET 8-K
Financial Results Vir Biotechnology, Inc. VIR

Vir Biotechnology Financial Results

Vir Biotechnology reported third-quarter 2026 financial results, ending the period with $901 million in cash and investments. The company highlighted upcoming Phase 3 data for its hepatitis delta program and the receipt of FDA Fast Track designation for its oncology candidate VIR-5500.

“We are entering an important period for Vir Bio, with meaningful catalysts across both hepatitis delta and oncology. We look forward to reporting topline ECLIPSE 1 data this quarter as we advance our goal to address the significant unmet need for patients with a therapy that can drive hepatitis delta virus to undetectable. In oncology, VIR-5500 achieved proof of concept and received FDA Fast Track designation, supporting our plans with Astellas to advance the program into pivotal trials next year. With momentum across both areas, we believe Vir Bio is well positioned to deliver meaningful value for patients and stakeholders.”

Marianne De Backer, President and Chief Executive Officer of Vir Biotechnology
4:11 PM ET 10-Q
Financial Results Green Thumb Industries Inc. GTBIF

Green Thumb Industries Q3 2026 Results: Net Loss of $4.83M

Green Thumb Industries Inc. reported total assets of $2.85 billion as of September 30, 2026, with cash and cash equivalents increasing to $316 million from $274 million at year-end 2025. The company maintained a strong balance sheet with accumulated earnings of $180.9 million, though total shareholders' equity slightly decreased to $1.86 billion due to changes in share capital and contributed deficit.

Key figure
Net loss $4.83M
4:11 PM ET 10-Q
Financial Results Sinclair, Inc. SBGI ▶ Call

Sinclair Q3 2026 Results: Turns Profitable, Net Income $43M

For the quarter ended September 30, 2026, Sinclair reported total revenue of $893 million and net income attributable to Sinclair of $43 million, a significant improvement from the $1 million loss in the prior year period. The company's balance sheet shows a reduction in total debt to $4.04 billion from $4.38 billion at the end of 2025, while cash and cash equivalents decreased to $659 million.

Key figure
Net income $43M
4:11 PM ET 10-Q
Financial Results Trex Co Inc TREX

Trex Co Q3 2026 Results: Net Income $52.5M, Up 1.4% YoY

Trex Company reported net sales of $359.5 million for the third quarter of 2026, a significant increase from $285.3 million in the prior year period. Despite higher sales, nine-month net income decreased slightly to $175.8 million compared to $188.1 million in 2025, primarily due to increased cost of sales and higher selling, general, and administrative expenses.

Key figure
Net income $52.5M · +1.4% YoY
4:11 PM ET 8-K
Financial Results Relay Therapeutics, Inc. RLAY

Relay Therapeutics Financial Results

Relay Therapeutics reported third quarter 2026 financial results, highlighting a cash position of approximately $849 million. The company provided clinical updates for its breast cancer and vascular anomalies programs, including an expected enrollment completion for the Phase 3 ReDiscover-2 trial in mid-2027.

Term
Q3 2026

“This quarter, we are very pleased by the pace of enrollment of our ReDiscover-2 trial for second-line breast cancer and also look forward to sharing updated ReInspire data for vascular anomalies at ASH. In addition, we continue to prepare for our frontline breast cancer trial testing the selective-selective combination of zovegalisib and atirmociclib, and we were highly encouraged by the data we saw from Pfizer’s FourLight-1 trial, which we believe showed the potential advantage of a CDK4-selective approach.”

Sanjiv Patel, M.D., President and Chief Executive Officer of Relay Therapeutics
4:11 PM ET 8-K
Financial Results Hubspot Inc HUBS

Hubspot Financial Results

HubSpot reported Q3 2026 revenue of $947.6 million, a 17% increase year-over-year, driven by 18% growth in subscription revenue. The company also reported a significant increase in GAAP net income to $83.0 million and expanded its customer base to over 311,000 while repurchasing $237.2 million of its common stock during the quarter.

Term
Q3 2026

“We are still in the early stages of a massive shift with AI, and we’re transforming HubSpot to lead in the Outcomes Era. AI is fundamentally changing software, from tools that help people do work to agents that do the work and deliver outcomes. We're transforming our product, pricing, go-to-market, and how we operate to capture this opportunity, and we made meaningful progress across these areas this quarter.”

Yamini Rangan, Chief Executive Officer
4:11 PM ET Form 4
Insider Selling Neogen Corp NEOG

Neogen CSO Jeremy Yarwood Sells $115K of Stock

Jeremy Yarwood, CSO, sold 9,051 shares of Neogen Corp at $12.67 a share, worth $115K in total on Nov 4, 2026. Shares held after the trade: 0 (-100.0%).

Value
$115K
Shares
9,051
Price
$12.67
Role
CSO
Holding change
-100.0%
Trade date
Nov 4, 2026
4:11 PM ET 8-K
Financial Results electroCore, Inc. ECOR

electroCore Financial Results

electroCore reported record third-quarter 2026 net sales of $9.7 million, a 12% increase year-over-year driven by growth in U.S. prescription sales within the VA channel. The company significantly reduced its GAAP net loss by 61% to $1.3 million and improved its Adjusted EBITDA loss by 67% to $0.7 million.

“This quarter reflects the early stages of a more efficient commercial organization. This quarter we delivered record net sales of $9.7 million, up approximately 12% from a year ago, while spending less to do it, leading to the lowest operating loss in our history. More importantly, we have evidence that the transformation is working. We are deliberately prioritizing profitable, sustainable long-term growth over short-term results, which underpins our confidence in accelerating revenue growth and an inflection point in positive Adjusted EBITDA in 2027.”

Joshua Lev, Co-Chief Executive Officer, President, and Chief Financial Officer
4:11 PM ET 8-K
Other 8-K Filing Monro, Inc. MNRO

Monro Other 8-K Filing

Monro, Inc. entered into an amendment to its Rights Agreement to extend the expiration date of its shareholder rights plan (poison pill) from November 6, 2026, to November 1, 2027. The Board of Directors approved the extension to protect the company and its shareholders while it continues an ongoing review of strategic alternatives.

Counterparty
Equiniti Trust Company, LLC
Term
through Nov 2027
4:11 PM ET 8-K
Financial Results ZoomInfo Technologies Inc. GTM

ZoomInfo Technologies Financial Results

ZoomInfo reported third quarter 2026 financial results with GAAP revenue of $308.8 million, a 3% decrease year-over-year. The company highlighted strength in its million-dollar customer cohort and continued focus on capital allocation, including the repurchase of 2.5 million shares and $34.8 million of its Senior Notes.

Term
Q3 2026

“ZoomInfo is central to how leading GTM teams and their AI agents get work done, and our headless context layer is now grounding AI agents across dozens of platforms our customers already use. Our largest customers continue to invest and grow with us, with our million dollar customer cohort the strongest it has ever been from an ACV and a logo perspective.”

Henry Schuck, ZoomInfo Founder and CEO
4:11 PM ET 8-K
Financial Results Sera Prognostics, Inc. SERA

Sera Prognostics Financial Results

Sera Prognostics reported Q3 2026 financial results, highlighting a 54% sequential increase in PreTRM test volume and a five-fold increase since Q1 2026. The company secured Medicaid coverage for its test in Florida, following a similar win in Illinois, and ended the quarter with $72.8 million in cash and marketable securities.

Term
Q3 2026

“The third quarter marked an important step forward as we continued our transition from evidence generation to commercial execution. We delivered strong growth in physician adoption and test volume, saw expanded reimbursement through a second state Medicaid coverage win in Florida, advanced our commercial payer initiatives, and continued to strengthen our clinical and health economic evidence base.”

Zhenya Lindgardt, President and Chief Executive Officer
4:11 PM ET 8-K
Financial Results Pacific Biosciences of California, Inc. PACB

Pacific Biosciences of California Financial Results

Pacific Biosciences reported Q3 2026 revenue of $40.6 million, driven by demand for its Revio and Vega sequencing systems. Alongside the results, the company announced that CFO Jim Gibson has stepped down and transitioned to an advisory role, with CEO Mark Van Oene serving as interim CFO during a search for a permanent successor.

Term
Q3 2026

“PacBio is entering an exciting phase as the investments we’ve made in our technology begin to unlock new opportunities. SPRQ-Nx is changing the economics of HiFi sequencing, while growing clinical adoption and strategic collaborations in population genomics and AI are expanding the markets we can serve. We have a tremendous opportunity ahead of us, and my focus is clear: sharpen our execution, prioritize what matters most, and translate the strength of our technology into sustainable growth.”

Mark Van Oene, President and Chief Executive Officer
4:11 PM ET 10-Q
Financial Results Arcus Biosciences, Inc. RCUS

Arcus Biosciences Q3 2027 Results

Arcus Biosciences reported total revenues of $67 million for the nine months ended September 30, 2026, a significant decrease from $214 million in the prior year period, primarily due to lower license and development services revenue. The company recorded a net loss of $347 million for the first nine months of 2026, compared to a net loss of $247 million in 2025, as operating expenses continued to outpace revenue.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.